Trending Topic

3D Rendered Medical Illustration of Male Anatomy - Colon Cancer; Ascending Colon.
17 mins

Trending Topic

Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked

Rat sarcoma virus (RAS) proteins are a family of prototypical oncogenes frequently mutated in human cancers. Mutations in the RAS gene account for 19% of all pathogenic alterations and are the subject of extensive research in molecular and clinical oncology.1 The RAS family consists of three major isoforms, namely the Harvey rat sarcoma virus (HRAS), the neuroblastoma RAS […]

Jorge Cortes: Ruxolitinib in myelofibrosis & rusfertide treatment in patients with phlebotomy-dependent polycythemia vera

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Published Online: Jul 18th 2022

Professor Jorge Cortes (Georgia Cancer Center, Augusta, GA, USA) summarizes three more important abstracts, the first two  from the 27th Congress of the European Hematology Association (EHA) looking at combination therapies with ruxolitinib, a JAK2 inhibitor. The third abstract was presented at the 2022 American Society of Clinical Oncology (ASCO) annual meeting, looking at rusfertide treatment in phlebotomy-dependent polycythemia vera patients.

Abstract: S197: ‘NAVITOCLAX PLUS RUXOLITINIB IN JAK INHIBITOR-NAÏVE PATIENTS WITH MYELOFIBROSIS: PRELIMINARY SAFETY AND EFFICACY IN A MULTICENTER, OPEN-LABEL PHASE 2 STUDY’ (00:10-01:29)

Abstract: S198: BET INHIBITOR PELABRESIB (CPI-0610) COMBINED WITH RUXOLITINIB IN PATIENTS WITH MYELOFIBROSIS — JAK INHIBITOR-NAÏVE OR WITH SUBOPTIMAL RESPONSE TO RUXOLITINIB — PRELIMINARY DATA FROM THE MANIFEST STUDY’ (01:29-02:30)

Abstract: 7003: Rusfertide (PTG-300) treatment in phlebotomy-dependent polycythemia vera patients. (02:30-03:49)

Disclosures: Jorge Cortes is consultant for, and has received grant/research support from Novartis, Pfizer, Takeda and Sun Pharma. He is also on the Advisory Board for Novartis and Pfizer.

Support: Interview and filming supported by Touch Medical Media. Interview conducted by Sophie Nickelson.

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Close Popup